France promises more Ebola aid as Congo’s response faces funding and vaccine gaps
Barrot seeks additional support, but no new approved sum was announced and research remains crucial.
France pledged stronger support for the response to Ebola in eastern Democratic Republic of Congo on October 3, linking assistance at the outbreak’s source to wider public-health preparedness.
Foreign Minister Jean-Noël Barrot said during his visit that he would seek additional humanitarian funding in French budget discussions, Reuters reported. France had allocated €13.4 million between January and July, but the announcement did not specify an approved new sum.
Ahead of the trip, the French foreign ministry said the visit would focus on Bunia in Ituri, where the epidemic was particularly severe. Its October 1 briefing identified support for frontline organizations, equipment and vaccine research among France’s priorities.
The ministry also described the obstacles confronting health workers: insecurity, displacement, shortages of medical staff and other outbreaks occurring at the same time. Those conditions make surveillance and access to treatment more difficult, even when funding is available.
Barrot’s visit preceded a national humanitarian conference scheduled in Paris for October 6. The ministry said the gathering would bring governments, aid organizations and other partners together to discuss humanitarian needs and financing.
The immediate distinction is between a political pledge and money delivered. France’s statements establish an intention to strengthen its contribution, while future budget decisions and aid reporting will show its scale. The outbreak response still depends on whether resources reach local teams and whether those teams can safely reach affected communities.
Research funding addresses a specific limitation in the response. In guidance dated August 31, WHO said no licensed vaccine existed for Bundibugyo virus disease, the form of Ebola disease at the center of the current emergency. Vaccines developed for another Ebola virus cannot automatically be assumed to provide the same protection.
The agency said animal studies suggested that Ervebo, licensed for Ebola virus disease, might offer some protection against Bundibugyo. But it cautioned that evidence in humans was insufficient to determine whether it worked or how much protection it might provide. WHO recommended use against Bundibugyo within a research protocol while that evidence was generated.
That distinction gives practical meaning to France's emphasis on vaccine research. It is a commitment to investigating an unanswered question, rather than proof that a ready-made preventive solution is available for the outbreak.
The guidance also preserved the role of routine health services. WHO said ordinary immunization should continue where safe, warning that interruptions could leave communities vulnerable to other diseases. Outbreak assistance therefore has to support an already burdened health system as well as the immediate emergency.
